Please use this identifier to cite or link to this item:
Title: Pattern of CNS relapse in acute lymphoblastic leukemia BCR-ABL positive, the importance of characterization of ABL1 mutations in cerebrospinal fluid.
Authors: Sanchez, R
Ayala, R
Alonso, RA
Ribera, J
García, O
Mercadal, S
Montesinos, P
Martino, R
Barba, P
González-Campos, J
Barrios, M
Lavilla, E
Gil, C
Bernal, T
Escoda, L
Abella, E
Amigo, ML
Moreno, MJ
Bravo, P
Guàrdia, R
Hernández-Rivas, JM
García-Guiñón, A
Piernas, S
Ribera, JM
Martínez-López, J
metadata.dc.contributor.authoraffiliation: [Sanchez,P] Biología Molecular Hematología. [Ayala,R; Martínez-López,J] Fundación Hospital Universitario 12 de Octubre. [Alonso,RA] Hematología, Hospital Universitario 12 de Octubre, Madrid. [Ribera,J; García,O] ICO-Hospital Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras. [Mercadal,S] ICO- Hospital Duran i Reynals (Bellvitge), Barcelona. [Montesinos,P] Hospital La Fe, Valencia. [Martino,R] Hospital Sant Pau. [Barba,P] Hospital Vall d’Hebron, Barcelona. [González-Campos,J] Hospital Virgen del Rocío, Sevilla. [Barrios,M] Hospital Carlos Haya, Málaga. [Lavilla,E] Hospital Lucus Augusti, Lugo. [Gil,C] Hospital General Universitario de Alicante, Alicante. [Bernal,T] Hospital Central de Asturias, Oviedo. [Escoda,L] Hospital Joan XXIII, Tarragona. [Abella,E] Hospital del Mar, Barcelona. [Amigo,ML] Hospital Meseguer, Murcia. [Moreno,MJ] Hospital Virgen de la Victoria, Málaga. [Bravo,P] Hospital Fuenlabrada, Fuenlabrada (Madrid). [Guàrdia,R] ICO-Hospital Josep Trueta, Girona. [Hernández-Rivas,JM] Hospital Universitario de Salamanca, Salamanca. [García-Guiñón,A] Hospital Arnau de Vilanova, Lleida. [Piernas,S] Hospital Parc Taulí, Sabadell (Barcelona), Spain.
Keywords: Médula ósea;Evolución clonal;ADN complementario;Proteínas de fusión bcr-abl;Humanos;Mesilato de imatinib;Incidencia;Masculino;Sistema nervioso;Leucemia-linfoma linfoblástico de células precursoras;Recurrencia;Tirosina
metadata.dc.subject.mesh: Medical Subject Headings::Anatomy::Hemic and Immune Systems::Immune System::Bone Marrow
Medical Subject Headings::Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Clonal Evolution
Medical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::Nucleic Acid Probes::DNA Probes::DNA, Complementary
Medical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Tyrosine Kinases::Proto-Oncogene Proteins c-abl::Fusion Proteins, bcr-abl
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Benzamides::Imatinib Mesylate
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Incidence
Medical Subject Headings::Check Tags::Male
Medical Subject Headings::Anatomy::Nervous System
Medical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Leukemia, Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma
Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Amino Acids::Amino Acids, Cyclic::Amino Acids, Aromatic::Tyrosine
Issue Date: Jun-2016
Publisher: Ferrata Storti Foundation
Citation: Sanchez R, Ayala R, Alonso RA, Ribera J, García O, Mercadal S, et al. Pattern of CNS relapse in acute lymphoblastic leukemia BCR-ABL positive, the importance of characterization of ABL1 mutations in cerebrospinal fluid. Haematologica. 2016. 101 (s1) E865
Abstract: He incidence of central nervous system (CNS) relapse among; patients with BCR/ABL-positive acute lymphoblastic leukemia (ALL) is 8-17%. Although tyrosine-kinase inhibitors (TKI), especially imatinib, are included in; the first-line treatment in these patients, their concentration in CNS is too low; to effectively prevent CNS relapse, making CNS prophylaxis mandatory. Aims: To study the frequency, predictors and evolution of BCR-ABL positive; ALL patients with CNS relapse in two consecutive clinical trials of the PETHEMA; group using imatinib and chemotherapy. As secondary objective we proposed; the introduction of a new method for the study of variants of uncertain; significance (VUS) in kinase domain of the BCR-ABL from cDNA of cerebrospinal; fluid (CSF) blasts, in order to adapt the TKI used in relapse according; to the clonal evolution from bone marrow (BM) to CSF cells.
ISSN: 0390-6078 (Print)
1592-8721 (Online)
Appears in Collections:01- Artículos - Hospital Regional de Málaga
01- Artículos - Hospital Virgen de la Victoria
01- Artículos - Hospital Virgen del Rocío

Files in This Item:
File Description SizeFormat 
SanchezR_PatternOfCNSRelapse.pdfAbstract60,24 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons